Copalia 10mg/160mg

Product Description

Uriach offers a wide range of products which includes copalia 10mg/160mg. Indications: treatment of essential hypertension in patients whose arterial pressure is not controlled sufficiently with amlodipine or valsartan when used individually. Therapeutic group: antihypertensive agent. Composition: copalia film-coated tablets, amlodipine besylate + valsartan. Characteristics: reduces arterial pressure in all states of hypertension (poldermans d.et al.t. Clin; produces an additional reduction of systolic/diastolic blood pressure, compared with that produced with amlodipine or valsartan when used individually, managing to control the tension figures (defined as diastolic/mean/systolic arterial pressure < 90 mmhg or a reduction >= 10 mmhg with respect to the basal value) in about 80-90% of patients.

Urquima - GRUPO URIACH

  • ES
  • 2015
    On CPhI since
Manufacturer/Innovator
Specifications
  • Selling Points
    Brand Name; International Approvals/Standards
  • Supplied from
    Spain

Urquima - GRUPO URIACH

  • ES
  • 2015
    On CPhI since
Manufacturer/Innovator

More Products from Urquima - GRUPO URIACH

  • Alvesco

    Product Alvesco

    Uriach offers a wide range of products which includes alvesco. Indications: helps to improve breathing, reducing the symptoms of asthma and the possibility of suffering an asthma attack. Therapeutic group: controlling asthma. Composition: the active ingredient is cyclesonid, and the other components are ethanol, anydro and a propellent gas (hfa-134a, norflurane).
  • Copalia 5mg/160mg

    Product Copalia 5mg/160mg

    'uriach offers a wide range of products which includes copalia 5mg/160mg. Indications: treatment of essential hypertension in patients whose arterial pressure is not controlled sufficienctly with amlodipine or valsartan used individually. . Therapeutic group: antihypertensive agent. Composition: copalia film-coated tablets, amlodipine besylate + valsartan. Characteristics: reduces arterial pressure in all states of hypertension (poldermans d.et al.t. Clin, produces an additional reduction of systolic/diastolic blood pressure, compared with that produced with amlodipine or valsartan when used individually, managing to control the tension figures (defined as diastolic/mean/systolic arterial pressure < 90 mmhg or a reduction >= 10 mmhg with respect to the basal value) in about 80-90% of patients. '

Recommended products